Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR ...

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Deep Apple could receive up to $812 million in payments plus royalties from Novo Nordisk. Novo Nordisk gains exclusive global rights to commercialize oral GPCR-targeted drugs. Get the Strategy to ...

Novo Nordisk has been actively pursuing licensing deals over the past six months. There are other good reasons to consider ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases Deep Apple is eligible to receive up to $812 ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity. U.S.-based Deep ...

(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...